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Abstract Pediatric patients with hemato-oncological malig-
nancies and neutropenia resulting from chemotherapy have a
high risk of acquiring invasive fungal infections. Oral antifungal
prophylaxis with azoles, such as fluconazole or itraconazole, is
preferentially used in pediatric patients after chemotherapy.
During this retrospective analysis, posaconazole was adminis-
tered based on favorable results from studies in adult patients
with neutropenia and after allogeneic hematopoietic stem
cell transplantation. Retrospectively, safety, feasibility, and
initial data on the efficacy of posaconazole were compared
to fluconazole and itraconazole in pediatric and adolescent
patients during neutropenia. Ninety-three pediatric patients
with hemato-oncological malignancies with a median age
of 12 years (range 9 months to 17.7 years) that had
prolonged neutropenia (>5 days) after chemotherapy or
due to their underlying disease, and who received flucona-
zole, itraconazole, or posaconazole as antifungal prophylaxis,
were analyzed in this retrospective single-center survey. The
incidence of invasive fungal infections in pediatric patients
was low under each of the azoles. One case of proven
aspergillosis occurred in each group. In addition, there were
a few cases of possible invasive fungal infection under flu-
conazole (n=1) and itraconazole (n=2). However, no such
cases were observed under posaconazole. The rates of poten-
tially clinical drug-related adverse events were higher in the
fluconazole (n=4) and itraconazole (n=5) groups compared
to patients receiving posaconazole (n=3). Posaconazole,
fluconazole, and itraconazole are comparably effective in
preventing invasive fungal infections in pediatric patients.
Defining dose recommendations in these patients requires
larger studies.
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mg/dL Milligrams per deciliter
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per day
mmol/L Millimol per liter
NHL Non-Hodgkin lymphoma
U/L Units per liter
Introduction
Invasive fungal infections belong to the most severe compli-
cations in patients with hemato-oncological malignancies dur-
ing neutropenia after intensive chemotherapy, representing a
leading cause for infectious mortality and morbidity in immu-
nocompromised children. Immunocompromised pediatric pa-
tients with prolonged severe neutropenia resulting from high-
dose chemotherapy have a high risk of acquiring invasive
fungal infections, especially with Aspergillus spp. and
Candida spp., so that a systemic antifungal prophylaxis is
indicated [1–5]. Immunosuppression and high-dose steroids
are additional risk factors for fungal infections [6]. Oral anti-
fungal prophylaxis with other azoles, fluconazole,
itraconazole, and voriconazole is preferentially used in pedi-
atric patients after chemotherapy. However, only a few studies
have been published on pediatric patients with hemato-
oncological malignancies, while antifungal prophylaxis seems
well described for adult patients [7–13]. Fluconazole shows
particularly good efficacy against Candida infections but not
with Aspergillus spp. [14–17]. Itraconazole has a broader
range of efficacy in comparison to fluconazole, which in-
cludes Aspergillus spp. and other rare mold infections
[18–20]. In pediatric patients with neutropenia after chemo-
therapy and hematopoietic stem cell transplantation (HSCT)
who received fluconazole and itraconazole, fungal break-
through infections occurred time and again [16, 21–25]. In
the hospital where the present analysis was performed, the
administration of fluconazole and itraconazole in pediatric
patients with neutropenia after high-dose chemotherapy and
HSCTwas associated with isolated cases of breakthrough in-
fections. Due to the favorable results of antifungal prophylaxis
with the broad-spectrum triazole posaconazole in adults
experiencing prolonged neutropenia or patients with graft-
versus-host disease (GvHD) [11, 12, 26], the oral antifungal
prophylaxis in pediatric patients after allogeneic HSCT was
changed to posaconazole in 2007. During the present survey,
the convincing results of these clinical studies in adults were
also seen in the first 60 pediatric patients (<12 years of age),
who received antifungal prophylaxis with posaconazole after
allogeneic HSCT, regarding efficacy, safety, and feasibility
[27]. This prompted another comparative analysis of three
azoles as antifungal prophylaxis; itraconazole, voriconazole,
and posaconazole. The retrospective analysis incorporated
150 immunocompromised pediatric patients after allogeneic
HSCT and evaluated the comparable efficacy of these three
azoles as antifungal prophylaxis [28].
Due to the excellent data from stem cell transplanted pedi-
atric patients, the antifungal prophylaxis in pediatric patients
after chemotherapywho experienced an anticipated prolonged
neutropenia of at least 5 days was changed as well.
Retrospectively, safety, feasibility, and initial data on the effi-
cacy of posaconazole were compared with those of flucona-
zole and itraconazole in 93 pediatric patients and adolescents
during the period of neutropenia after chemotherapy or during
neutropenia caused by an underlying disease.
Materials and methods
Survey design
This analysis is a single-center, retrospective, non-randomized
survey of 93 pediatric patients who received fluconazole,
i t raconazole, or posaconazole as oral antifungal
monoprophylaxis during the phase of intensive induction,
consolidation and re-induction chemotherapy, or during the
period of neutropenia caused by an underlying disease. The
survey was performed at the Department of Pediatric
Hematology and Oncology, University Children’s Hospital
Tuebingen, Germany. The patient cohorts consisted of pediat-
ric patients and adolescents with hemato-oncological malig-
nancies, starting chemotherapy between January 2006 and
January 2013 (Table 1). The analysis included only pediatric
patients who were diagnosed with prolonged neutropenia
(neutrophil counts<500/μL; >5 days) when receiving antifun-
gal prophylaxis. Antifungal monoprophylaxis with one of the
three azoles began 24 h after the end of the chemotherapy
cycle in pediatric patients with high-risk acute lymphoblastic
leukemia (ALL), ALL relapse, acute myeloid leukemia
(AML), AML relapse, non-Hodgkin lymphoma (NHL),
Hodgkin lymphoma, osteosarcoma, Ewing sarcoma, and solid
tumors, and ended at a minimum of one day before the start of
chemotherapy. The treatment period was defined as the days
when antifungal prophylaxis was orally administered with one
of the three azoles. Pediatric patients with thalassemia major,
aplastic anemia, or granulocytopenia were given antifungal
monoprophylaxis during the whole period of neutropenia.
Thirty-one of the 93 pediatric patients received antifungal
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prophylaxis with fluconazole at a dosage of 1×5 mg per kilo-
gram of body weight per day (mg kg BW−1 d−1) (maximum
1×400 mg/day), while 32 were given antifungal prophylaxis
with itraconazole at a dosage of 2×5 mg kg BW−1 d−1 (max-
imum 2×200 mg/day). Thirty other pediatric patients received
antifungal prophylaxis with posaconazole 3×4 mg kg
BW−1 d−1 (maximum 3×200 mg/day). The primary objec-
tives of this survey were to analyze the safety, feasibility,
and efficacy of antifungal monoprophylaxis with fluconazole,
itraconazole, or posaconazole for pediatric patients with
hemato-oncological malignancies and neutropenia resulting
from chemotherapy. The secondary objectives were to assess
the incidence of invasive fungal infection with Aspergillus
spp., Candida spp., or other fungal species. The observation
period was defined as the time during the whole chemothera-
py, including chemotherapy cycles. It started one day before
the beginning of antifungal prophylaxis with one of the three
azoles and ended three weeks after the last dosing or until the
Table 1 Patient characteristics
ALL acute lymphoblastic
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No. of patients (%)
Gender
Male 21 (67.7) 14 (43.8) 12 (40.0) 0.089
Female 10 (32.3) 18 (56.3) 18 (60.0) (Chi-square)
Age group
<6 years 8 (25.8) 7 (21.9) 9 (30.0)
7–11 years 4 (12.9) 8 (25.0) 9 (30.0) 0.426
12 to <18 years 19 (61.3) 17 (53.1) 12 (40.0) (Chi-square)
Diagnosis
ALL 14 (45.2) 6 (18.8) 4 (13.3) 0.009
ALL relapse 1 (3.2) 7 (21.9) 9 (30.0) 0.018
AML 2 (6.5) 12 (37.5) 1 (3.3) 0.0003
AML relapse 0 (0.0) 3 (9.4) 3 (10.0) 0.215
MDS 0 (0.0) 0 (0.0) 1 (3.3) 0.346
NHL 6 (19.4) 1 (3.1) 3 (10.0) 0.114
Hodgkin lymphoma 3 (9.7) 1 (3.1) 0 (0.0) 0.163
Thalassemia major 0 (0.0) 0 (0.0) 1 (3.3) 0.346
Aplastic anemia 0 (0.0) 0 (0.0) 5 (16.7) 0.004
Granulocytopenia 0 (0.0) 0 (0.0) 1 (3.3) 0.346
Osteosarcoma 4 (12.9) 1 (3.1) 0 (0.0) 0.065
Ewing sarcoma 1 (3.2) 1 (3.1) 0 (0.0) 0.614
Solid tumor 0 (0.0) 0 (0.0) 2 (6.7) 0.117
Systemic corticosteroids in mg kg BW−1 d−1
Dexamethasone 0.708
≥2.0 0 (0.0) 0 (0.0) 0 (0.0 Fisher’s exact t
<2.0 but ≥1.0 0 (0.0) 0 (0.0) 1 (3.3)
<1.0 but ≥0.5 9 (29.0) 10 (31.3) 8 (26.7)
<0.5 8 (25.8) 5 (15.6) 5 (16.7)
Prednisone/prednisolone 0.961
≥2.0 4 (12.9) 0 (0.0) 1 (3.3) Fisher’s exact t
<2.0 but ≥1.0 4 (12.9) 1 (3.1) 1 (3.3)
<1.0 but ≥0.5 0 (0.0) 0 (0.0) 2 (6.7)
<0.5 0 (0.0) 0 (0.0) 1 (3.3)
Methylprednisolone k proportions test
≥2.0 0 (0.0) 0 (0.0) 2 (6.7) 0.117
<2.0 but ≥1.0 0 (0.0) 0 (0.0) 1 (3.3) 0.346
<1.0 but ≥0.5 0 (0.0) 0 (0.0) 0 (0.0) 1
<0.5 0 (0.0) 0 (0.0) 0 (0.0) 1
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occurrence of a proven or probable fungal infection. For some
pediatric patients, the observation period continued until
shortly before the start of the conditioning regimen of
the planned stem cell transplantation. The treatment period
comprises days on which an antifungal monoprophylaxis
with one of the three azoles, fluconazole, itraconazole, or
posaconazole, was administered. The patients received flu-
conazole from 2006 to 2011, itraconazole from 2006 to
2012, and posaconazole from 2008 to 2013.
Assessment of safety and tolerance
For all of the 93 pediatric patients included in this survey,
adverse events during the observation period and caused
by one of the three azoles were graded according to the
current United States National Cancer Institute’s Common
Terminology Criteria for Adverse Events [29]. During the
observation period, an analysis of liver and kidney param-
eters, as well as electrolytes, was performed. The analysis
of hepatic toxicity included transaminases alanine amino-
transferase (ALT, normal range≤39 U/L) and aspartate
aminotransferase (AST, normal range≤39 U/L), cholestasis
parameters total bilirubin (normal range≤1.1 mg/dL) and
direct bilirubin (normal range≤0.3 mg/dL), and alkaline
phosphatase (AP, normal range≤320 U/L). The evaluation
of kidney toxicity involved the examination of serum cre-
atinine (normal range≤0.7 mg/dL) and urea (normal
range≤46 mg/dL). In addition, an analysis of electrolytes
potassium (normal range≥3.4 mmol/L), calcium (normal
range≥2.0 mmol/L), and phosphate (normal range 1.1–
1.5 mmol/L) was carried out. We assessed clinically rele-
vant elevations of>1.5 and>2.5 times the normal values of
hepatic and renal parameters, and a decrease of potassium
values<3.4 mmol/L or<2.4 mmol/L, calcium values
<2.0 mmol/L or<1.8 mmol/L, and phosphate values
<1.1 mmol/L or<0.8 mmol/L. During the antifungal
monoprophylaxis with one of the three azoles, fluconazole,
itraconazole, or posaconazole, analysis of blood cell counts
and hepatic and kidney function was performed a mini-
mum of two times weekly. The evaluation of electrolytes
was done up to a minimum of 3 weeks after the end of
treatment with antifungal monoprophylaxis. Blood analyses
were documented the day before the start of oral
monoprophylaxis with one of the three azoles (baseline),
as well as the maximum or minimum values during and at
the end, defined as the last day of treatment with antifun-
gal prophylaxis.
Assessment of efficacy
All patients were monitored for clinical signs of infection,
laboratory analyses, and radiological workup if indicated.
The absence of clinically relevant symptoms such as fever or
coughing and deviations of laboratory values beyond the nor-
mal range indicating a fungal infection were regarded as suc-
cessful treatment. According to the European Organization for
Research and Treatment of Cancer/National Institute of
Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) criteria of 2002 and 2008, invasive fungal
infections were classified as proven, probable, and possible
[30, 31]. The galactomannan antigen was measured until
the occurrence of fever with duration of 72 h ≥38.5 °C
by the Platelia™ Aspergillus enzyme-linked immunosorbent
assay according to the manufacturer’s protocol (Bio-Rad
Laboratories, Munich, Germany). The non-occurrence of
clinical or microbiological signs of invasive fungal break-
through infection during the observation period with anti-
fungal monoprophylaxis was considered as successful anti-
fungal treatment.
Statistical analysis
This retrospective analysis included 93 pediatric patients who
received antifungal monoprophylaxis with fluconazole,
itraconazole, or posaconazole after chemotherapy or during
immunosuppressant therapy. The statistical comparison of dif-
ferences between the results and normal range values of liver
and kidney parameters and electrolytes was performed by
one-sample t-tests. This took into account the 95 % confi-
dence intervals. The inferential statistical analysis between
the baseline values and maximum and minimum parameters,
as well as the parameters at the cessation of antifungal
monoprophylaxis, was performed using the Friedman two-
way analysis of variance (ANOVA) by ranks. Values were
only considered significant if they were above the age-
adjusted reference. The analysis of hepatic and renal function
parameters are presented as mean values + standard deviation
(SD). Differences in the frequencies of medication groups, for
example at primary diagnosis, application of steroids, or inci-
dence of breakthrough infections when comparing the three
patient groups (with n=31, n=32, and n=30 patients), were
tested by the k proportions test. Medications with available
contingency tables for up to four classes were first calculated
using Fisher’s exact test. This was followed by a k proportions
test for each individual class (i.e., first a global test for the
entire frequency table and then separate tests for each class).
For statistical comparison of the three groups regarding clin-
ical and laboratory adverse events during treatment with anti-
fungal prophylaxis, the arithmetic mean values of the three
medication groups with a one-way ANOVA were tested for
differences. Values of p<0.05 (*), p<0.01 (**) and p<0.001
(***) were defined as significant. XLSTAT 2013 (AddinSoft,
Paris, France) or GraphPad Prism® Version 5.04 for Windows
(GraphPad Software, La Jolla, CA, USA) were used for the
statistical analyses. Graphs were created with GraphPad
Prism® Version 5.04 for Windows.
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Results
Patient characteristics
This single-center analysis involved the evaluation of 93
pediatric patients with hemato-oncological malignancies
aged between 9 months and 17.7 years who received an
antifungal monoprophylaxis with fluconazole, itraconazole,
or posaconazole during a period of prolonged neutropenia
(>5 days). The median age in the fluconazole group was
14 years (range 1–17.5 years), while the itraconazole and
posaconazole groups had medians of 12 years (range 1–
17.7 years) and 11 years (range 9 months to 17.4 years),
respectively. Significant differences in clinical characteris-
tics were noted regarding the number of children with ALL
(p=0.009), ALL relapse (p=0.018), and AML (p=0.0003)
included in this analysis, but no significant differences were
found in the AML relapse group (p=0.215). The percentage
of all these types of diagnoses of the fluconazole group (i.e.,
54.8 % acute leukemia; 17 of 31 patients) was comparable
Table 2 Treatment regimens
Characteristics Fluconazole (n=31) Itraconazole (n=32) Posaconazole (n=30) p-Value
No. of patients (%)
Alkylating antineoplastic agent CPM 24 (77.4) 8 (25.0) 8 (26.7) <0.0001
Dacarbazine 2 (6.5) 0 (0.0) 1 (3.3) 0.350
Ifosfamide 10 (32.3) 9 (28.1) 6 (20.0) 0.548
Melphalan 0 (0.0) 0 (0.0) 1 (3.3) 0.346
Anthracyclines Daunorubicin 12 (38.7) 14 (43.8) 8 (26.7) 0.360
Doxorubicin 13 (41.9) 3 (9.4) 1 (3.3) 0.0001
Idarubicin 2 (6.5) 15 (46.9) 1 (3.3) <0.0001
Antimetabolites
Folic acid analogues Methotrexate 23 (74.2) 10 (31.3) 6 (20.0) <0.0001
Purine analogues Clofarabine 0 (0.0) 1 (3.1) 3 (10.0) 0.145
Fludarabine 1 (3.2) 4 (12.5) 2 (6.7) 0.369
Nelarabine 0 (0.0) 0 (0.0) 1 (3.3) 0.346
Tioguanine 3 (9.7) 7 (21.9) 3 (10.0) 0.282
6-Mercaptopurine 9 (29.0) 5 (15.6) 5 (16.7) 0.345
Pyrimidine analogues Cytarabine 22 (71.0) 26 (81.3) 15 (50.0) 0.028
2-CDA 1 (3.2) 3 (9.4) 0 (0.0) 0.179
Enzymes Asparaginase 12 (38.7) 10 (31.3) 9 (30.0) 0.735
Platinum complex compounds Carboplatin 1 (3.2) 0 (0.0) 0 (0.0) 0.364
Cisplatin 4 (12.9) 1 (3.1) 0 (0.0) 0.065
Topoisomerase inhibitors Etoposide 13 (41.9) 17 (53.1) 6 (20.0) 0.025
Mitoxantrone 2 (6.5) 10 (31.3) 0 (0.0) 0.001
Topotecan 1 (3.2) 0 (0.0) 0 (0.0) 0.364
Vinca alkaloids Vinblastine 0 (0.0) 0 (0.0) 1 (3.3) 0.346
Vincristine 19 (61.3) 11 (34.4) 10 (33.3) 0.042
Vindesine 8 (25.8) 6 (18.8) 5 (16.7) 0.648
Intrathecal medication Cytarabine 14 (45.2) 24 (75.0) 13 (43.3) 0.018
methotrexate 22 (71.0) 26 (81.3) 12 (40.0) 0.002
Predniso(n)/lon 14 (45.2) 24 (75.0) 11 (36.7) 0.006
Antibodies ATG 0 (0.0) 0 (0.0) 1 (3.3) 0.346
Blinatumomab 0 (0.0) 0 (0.0) 1 (3.3) 0.346
CD19 antibody 0 (0.0) 1 (3.1) 0 (0.0) 0.382
Rituximab 0 (0.0) 0 (0.0) 2 (6.7) 0.117
Tyrosine kinase inhibitors Nilotinib 0 (0.0) 0 (0.0) 1 (3.3) 0.346
Imatinib 0 (0.0) 1 (3.1) 0 (0.0) 0.382
ATG anti-thymocyte globulin; CPM cyclophosphamide; CSA ciclosporin A; 2-CDA 2-chloro-2′-deoxyadenosine
Statistical tests: k proportions test with XLSTAT 2013
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(p=0.1611) to the posaconazole group (56.7 %; 17 of 30
patients), but significantly different (p=0.0054) from the
itraconazole group (87.5 %; 28 of 32 patients; see
Table 1). Information on chemotherapy regimens is pre-
sented in Table 2.
Treatment and observation period
The median observation periods were 135 days (range 47–212
days) for the fluconazole group, 104 days (range 47–186) for
the itraconazole group, and 107 days (range 28–236 days) for
the posaconazole group. The median treatment period was
116 days (range 25–189 days) for the fluconazole group,
85 days (range 23–164 days) for the itraconazole group, and
86 days (range 6–214 days) for the posaconazole group.
Mortality
Seven (7.5 %) of the 93 pediatric patients died during the
observation period. None of the patients included in the anal-
ysis died of invasive fungal infection. Four patients died due
to a relapse of their primary diagnosis. Two patients died of
multiple organ failure due to sepsis, while another one died of
cardiac failure after chemotherapy.
Neutropenia
The count of prolonged neutropenic periods (neutrophil
counts <500/μL; >5 days) were similar in all three groups,
with medians of two periods (range 1–7) in the fluconazole
group, two periods (range 1–6) in the itraconazole group, and
Table 3 Clinical and laboratory
adverse events during antifungal
prophylaxis









No. of patients (%)
Drug-related adverse events
Clinical (total) 4 (12.9) 5 (15.6) 3 (10.0) 0.804
Fever 0 (0.0) 1 (3.1) 0 (0.0) 0.382
Headache 1 (3.2) 0 (0.0) 0 (0.0) 0.364
Nausea 1 (3.2) 1 (3.1) 1 (3.3) 0.999
Diarrhea 2 (6.5) 1 (3.1) 0 (0.0) 0.362
Exanthema 0 (0.0) 1 (3.1) 0 (0.0) 0.382
Abdominal pain 0 (0.0) 1 (3.1) 2 (6.7) 0.338
Increase in alanine aminotransferase
>1.5×normal value 39 U/L 8 (25.8) 7 (21.8) 3 (10.0) 0.267
>2.5×normal value 39 U/L 4 (12.9) 4 (12.5) 5 (16.7) 0.874
Increase in aspartate aminotransferase
>1.5×normal value 39 U/L 4 (12.9) 2 (6.6) 5 (16.7) 0.435
>2.5×normal value 39 U/L 3 (9.7) 3 (9.4) 1 (3.3) 0.571
Increase in alkaline phosphatase
>1.5×normal value 320 U/L 1 (3.2) 0 (0.0) 0 (0.0) 0.364
>2.5×normal value 320 U/L 0 (0.0) 0 (0.0) 0 (0.0) 1.0
Increase in total bilirubin
>1.5×normal value 1.1 mg/dl 1 (3.2) 2 (6.3) 2 (6.7) 0.807
>2.5×normal value 1.1 mg/dl 0 (0.0) 0 (0.0) 0 (0.0) 1.0
Increase in direct bilirubin
>1.5×normal value 0.3 mg/dl 2 (6.5) 3 (9.4) 2 (6.7) 0.887
>2.5×normal value 0.3 mg/dl 0 (0.0) 3 (9.4) 1 (3.3) 0.177
Increase in creatinine
>1.5×normal value 0.7 mg/dl 1 (3.2) 0 (0.0) 1 (3.3) 0.585
>2.5×normal value 0.7 mg/dl 0 (0.0) 0 (0.0) 0 (0.0) 1.0
Increase in urea
>1.5×normal value 46 mg/dl 1 (3.2) 0 (0.0) 0 (0.0) 0.364
>2.5×normal value 46 mg/dl 0 (0.0) 0 (0.0) 0 (0.0) 1.0
Decrease in potassium
<3.4 mmol/L 2 (6.5) 3 (9.4) 2 (6.7) 0.867
<2.4 mmol/L 0 (0.0) 0 (0.0) 0 (0.0) 1.0
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two periods (range 1–6) in the posaconazole group. The me-
dian durations of the prolonged neutropenic periods were
7 days (range 5–47 days), 9 days (range 6–78 days), and 7 days
(range 5–214 days), with means of 8.9±3.2, 12.6±6.1, and
17.4±11.4, respectively.
Adverse events
The spectrum of drug-related adverse events caused by one of
the three azoles was characterized primarily by gastrointesti-
nal symptoms such as abdominal pain, nausea, or diarrhea in
all three groups. Other adverse events in the fluconazole group
were headache, while patients in the itraconazole group expe-
rienced fever and exanthema (Table 3). Adverse events that
may be related to antifungal treatment were observed in four
patients in the fluconazole group, in five patients in the
itraconazole group, and in three patients in the posaconazole
group. The differences between these three groups were not
significant (p=0.804). Due to adverse events, oral antifungal
prophylaxis was withdrawn for two of the four patients treated
with fluconazole, for three of the five patients treated with
itraconazole, and for one of the three patients treated with
posaconazole.
Efficacy analysis
All 93 pediatric patients were included in the efficacy analysis
(Table 4). Overall, there were two invasive fungal break-
through infections in the fluconazole group, three in the
itraconazole group, and one in the posaconazole group, ac-
cording to the EORTC guidelines [30, 31]. In each of the three
azole groups, there was one proven fungal infection. Probable
infections did not occur. Possible fungal infections were seen
in one patient in the fluconazole group and two patients in the
itraconazole group.
In the fluconazole group, one patient with high-risk ALL,
who presented with neutropenia and coughs, experienced an
Aspergillus spp. infection with typical fungus infiltrates in the
lungs and brain. The galactomannan antigen was positive in
more than two consecutive blood analyses. There was also
positive microbiological detection in the sputum. An antifun-
gal combination therapy with caspofungin, voriconazole, and
liposomal amphotericin B was given. Both the pulmonary
nodule and two cerebral foci were resected. After clinical dis-
charge, antifungal therapy was given with posaconazole for a
further six months. During this time, there were no more signs
of invasive fungal infection. A possible invasive infection was
observed in this group for one patient suffering from ALL.
The computed tomography (CT) scan showed foci that were
suspected to be fungi herds. However, galactomannan antigen
was negative.
In the itraconazole group, one patient with AML experi-
enced thoracic pain and fever during the neutropenia period
between chemotherapy cycles. The CT scan showed an
Aspergillus pneumonia with a halo sign and increase in
galactomannan antigen. The patient was treated with a triple
antifungal prophylaxis including caspofungin, voriconazole,
and liposomal amphotericin B. After resection of the pulmo-
nary foci, antifungal therapy was continued with antifungal
monotherapy with liposomal amphotericin B. The patient re-
ceived oral antifungal therapy with posaconazole after clinical
discharge for a further five months. During this time, there
was no sign of invasive fungal infection. In this group, two
possible fungal infections occurred in patients with AMLwho
underwent chemotherapy cycles. Typical fungus lung infil-
trates were found on the CT scan. In both patients, the
galactomannan antigen was not detectable. A lung lavage
was not performed.
In the posaconazole group, one pa t ien t wi th
granulocytopenia experienced fever and pain in the right low-
er abdomen. Up to that point, the pediatric patient had been
treated with posaconazole antifungal monoprophylaxis for a
period of 104 days. An appendectomy was performed and its
biopsy material showed evidence of an Aspergillus infection.
The galactomannan antigen and blood cultures were negative
during the entire period when antifungal prophylaxis with
posaconazole was given. The antifungal prophylaxis was con-
tinued with posaconazole in therapeutic dosage for another
110 days after the appendectomy until the planned stem cell
transplantation. At the time of HSCT, intravenous antifungal
prophylaxis was given with liposomal amphotericin B during
the conditioning regimen and on day 1 after HSCT with
caspofungin. Shortly before clinical discharge, there was a
change to antifungal oral monoprophylaxis with posaconazole
until reaching immune reconstitution (CD3+ cells 200/μL and
CD4+ cells to 100/μL; until day 120 after transplantation).












2 3 1 0.626
Aspergillus spp.
Proven 1 1 1 0.999
Probable – – –
Possible 1 2 – 0.380
Candida spp.
Proven – – –
Probable – –
Possible – – –
Others – – –
Statistical tests: k proportions test with XLSTAT 2013
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There were no more signs of an invasive fungal infection
during the entire period after stem cell transplantation. A pos-
sible invasive fungal infection did not occur in this patient
group.
A probable invasive infection did not occur in any of the
three azole groups.
Safety and tolerance
The blood analysis of liver and kidney parameters showed
a significant increase beyond the upper normal limit of
ALT between baseline and maximum in all three groups,
i.e., fluconazole (p=0.031), itraconazole (p=0.015), and
posaconazole (p=0.007), and a significant increase of
AST between baseline and maximum in the fluconazole
(p=0.049) and posaconazole groups (p=0.005) (Fig. 1).
An increase in ALT of>1.5 and 2.5 times the normal
value occurred in a total of 12 pediatric patients in the
fluconazole group, 11 pediatric patients in the itraconazole
group, and eight pediatric patients in the posaconazole
group. AST>1.5 and 2.5 times the normal value occurred in
a total of seven pediatric patients in the fluconazole group, five
pediatric patients in the itraconazole group, and six pediatric
patients in the posaconazole group (Table 3). The total and
direct bilirubin and AP showed no significant increase above
the normal values during antifungal prophylaxis with any of
the three azoles. Kidney parameters creatinine and urea were
not significantly elevated beyond the upper limit of the normal
range during antifungal monoprophylaxis in any of the
treatment groups (Fig. 2). In all three groups, there was
no significant decrease in potassium during antifungal pro-
phylaxis with any of the three azoles.
Fig. 1 Hepatotoxicity. The data show mean values + standard deviation
(SD) of transaminases and total bilirubin on the day before the start of oral
antifungal prophylaxis (Baseline) and maximum values during
(Maximum) and at the end (End) of treatment with fluconazole,
itraconazole, and posaconazole. Normal values are indicated by the dot-
ted lines. a Mean + SD of serum concentration of aspartate aminotrans-
ferase (AST) (normal<39 U/L). ); p-values maximum compared to base-
line: fluconazole (p=0.049), itraconazole (p>0.05), and posaconazole
(p=0.005). b Mean + SD of serum concentration of alanine
aminotransferase (ALT) (normal<39 U/L); p-values maximum compared
to baseline: fluconazole (p=0.031), itraconazole (p=0.015), and
posaconazole (p=0.007). c Mean + SD of serum concentration of
total bilirubin (normal<1.1 mg/dL); p-values maximum compared to
baseline: fluconazole (p>0.05), itraconazole (p>0.05), and
posaconazole (p>0.05). None of the changes in the ALT, AST, or
total bilirubin serum concentrations were clinically relevant. Statistical
significance was tested by the Wilcoxon matched-pairs signed-rank
test. *p<0.05; **p<0.01
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Discussion
The goal of antifungal prophylaxis treatment in pediatric pa-
tients with prolonged neutropenia is to prevent invasive fungal
infections, thereby minimizing mortality. While several
evidence-based guidelines are available for adults with
hemato-oncological malignancies [32–36], there are only lim-
ited data on pediatric patients [37, 38]. Due to the favorable
results of oral antifungal prophylaxis with posaconazole in
adults with myelodysplastic syndromes (MDS) and AML in
randomized clinical trials involving more than 300 high-risk
patients with neutropenia and more than 300 transplanted pa-
tients with GvHD [11, 12], we have also been using oral
antifungal prophylaxis with posaconazole at our clinic since
2007. The excellent results in the first 60 pediatric patients
treated with posaconazole after HSCT and comparably suc-
cessful analysis of posaconazole with itraconazole and
voriconazole in 150 pediatric patients after allogeneic HSCT
[27, 28] were the decisive factors to perform this retrospective
analysis. This analysis, which includes 93 pediatric patients
with a median age of 12 years, shows that the incidence of
invasive fungal infections in pediatric patients was low under
each of the three azoles posaconazole, itraconazole, and
fluconazole.
In each of the three treatment groups, there was one proven
fungal infection, but no occurrence of probable fungal
infections. Possible fungal infections were observed in
both the itraconazole and fluconazole groups, but not in
the posaconazole group. The occurrence of proven fungal
infection in all three groups raises the question as to
whether the dosage and resorption of the extended-
spectra azoles were adequate, as regular assessment of
trough levels had not been performed.
The data on pediatric patients regarding the efficacy, safety,
and tolerability of posaconazole are mainly confined to anal-
yses of small numbers of patients. A multicenter retrospective
analysis, which examined the treatment of proven or probable
invasive fungal infections, showed a remission in 9 of the 15
pediatric patients under salvage therapy with posaconazole
[39]. Another retrospective study in 15 children with proven
(n=1), probable (n=10), or possible (n=1) fungal infection
after HSCT or neutropenia after chemotherapy showed that
posaconazole, as secondary prophylaxis, is to be regarded as
being safe and well tolerated by children [40]. After 90 days of
treatment with posaconazole, significantly improved radiolog-
ical results were shown in nine pediatric patients. Twelve
months after the onset of fungal infection in 12 patients, the
survival rate was 91.67 %.
In a single-center retrospective study, 2 of 53 pediatric pa-
tients given intravenous and then oral antifungal prophylaxis
with itraconazole after HSCT experienced a proven fungal
infection [21]. A comparison of the efficacy of itraconazole,
voriconazole, fluconazole, and posaconazole as antifungal
prophylaxis in adults showed that invasive fungal infections
occurred the least often (in 3 % of cases) in patients given
posaconazole, while patients treated with fluconazole ex-
perienced invasive fungal infections at the highest rate
(25 % of cases) [41]. More effective prevention of inva-
sive fungal infections and, thus, an improvement in the
survival rate was observed with posaconazole antifungal
prophylaxis in 2 % of 304 adult patients treated, compared
to itraconazole and fluconazole, where fungal infection
occurred in 8 % of the cases [11].
The results of the present survey show that clinical, poten-
tially azole-related adverse events are higher in the flucona-
zole (n=4) and itraconazole (n=5) groups than in the
posaconazole group (n=3). However, these results are not
statistically significant.
Mainly gastrointestinal adverse events such as nausea, di-
arrhea, and abdominal pain occurred in all three groups with
Fig. 2 Nephrotoxicity. The data show mean values + standard deviation
(SD) of renal parameters on the day before the start of oral antifungal
prophylaxis (Baseline) andmaximum (Maximum) or minimum (Minimum)
values during and at the end of fluconazole, itraconazole, and posaconazole
treatment. Normal values are indicated by the dotted lines. aMean + SD of
serum concentration of creatinine (normal<0.7 mg/dL). b Mean + SD of
serum concentration of potassium (normal>3.4 mmol/L). Statistical signif-
icance was tested by the Wilcoxon matched-pairs signed-rank test
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the same frequency. Fortunately, no azole-associated periph-
eral neuropathy side effect was observed in any of the patients
from the three groups. Similar results have been reported in
several studies on long-term triazole therapy [42, 43]. These
results can probably be attributed to the cessation of antifungal
prophylaxis with one of the azoles 24 h before the start of
chemotherapy and 24 h after chemotherapy with the vinca
alkaloid.
In a multicenter randomized trial with adults, the compar-
ison of itraconazole with fluconazole showed that itraconazole
is more effective as a long-term prophylaxis. However, while
taking itraconazole (both intravenous and oral), gastrointesti-
nal side effects occurred significantly (p=0.02) more often
than with fluconazole recipients [16].
In a randomized, double-blind trial of 600 patients after
stem cell transplantation with GvHD, antifungal prophylaxis
of invasive fungal infections with oral posaconazole in 301
patients was compared to oral fluconazole in 299 patients.
Gastrointestinal disorders such as diarrhea, nausea, and ab-
dominal pain occurred more often in the fluconazole group
(18 %) than in the posaconazole group (14 %) [44]. In an
analysis using data derived from 12 clinical studies of flucon-
azole as prophylaxis or treatment for a variety of fungal infec-
tions including 562 predominantly immunocompromised pe-
diatric patients, the most common side effects were associated
with the gastrointestinal tract (7.7 %) [44]. In studies which
analyzed the safety and tolerability of posaconazole in pediat-
ric patients, side effects such as nausea and vomiting occurred
at varying frequencies [27, 39, 40].
In the present analysis, the transaminases ALT and AST
increased significantly beyond the normal ranges during anti-
fungal prophylaxis, whereas total bilirubin, direct bilirubin,
creatinine, urea, and potassium showed no significant changes
during the treatment. Changes in the transaminases of the
itraconazole and posaconazole groups in the present investi-
gation correspond to prior observations made at our hospital
during antifungal prophylaxis with these azoles [27, 28]. In a
retrospective single-center study, 10 (18.9 %) out of the 53
pediatric patients that received antifungal prophylaxis with
itraconazole after HSCTwere found to have at least a doubling
of the baseline value of AST [21]. In different published
studies with immunocompromised pediatric and juvenile
patients suffering from hemato-oncological malignancies,
transaminases ALT and AST were also increased under
antifungal prophylaxis and therapy with fluconazole in
6–18 % of the recipients [44].
In summary, in the present survey, the incidence of invasive
fungal infections in pediatric patients was similarly low under
each of the azoles during the observation period. One case of
proven aspergillosis occurred in each group.While this can be
explained in the case of fluconazole, it remains an open ques-
tion as to why extended-spectra azoles were not capable of
preventing these breakthrough infections. Inadequate dosing
and/or inadequate trough levels due to malabsorption may
have contributed to the treatment failures. A few cases of
possible invasive fungal infection under fluconazole and
itraconazole, but none under posaconazole, were observed.
Potentially clinical drug-related adverse events were similar
in the three treatment groups. Laboratory parameters were com-
parable during fluconazole, itraconazole, and posaconazole
treatment. Larger cohorts and a prospective setting are needed
in order to establish the efficacy of prophylactic use of
extended-spectra azoles in this patient cohort.
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